Furthermore, investigations into colon, gastric, ovarian, and liver cancer have utilized various interventions, from intratumoral injections of Nav1.5 antibodies to knockdown of β3 Nav1.7 in cells, reflecting the diverse approaches employed to modulate VGSCs across different cancer types [46, 51, 64, 75]. Here, SCN5A is linked to cancer.